Caplan: New Mammogram Recommendations Accurate, but Not Right
While the data may support pushing back the timeline for routine mammograms from age 40 to 50 for women, Arthur Caplan questions the decision in his most recent MSNBC column saying that "there is every reason to doubt that the numbers they compiled will be sufficient to overturn a medical practice that carries so much ethical weight for women." More importantly, they probably shouldn't.
To read the entirety of Caplan's column, read below or click the link above.
Summer Johnson, PhD
Mammogram advice accurate but not 'right'
by Arthur Caplan, PhD
Did you hear an enormous thud around 3 p.m. yesterday? That was the sound of Secretary of Health and Human Services Kathleen Sebelius throwing her scientists under a bus.
Earlier this week, the U.S. Preventive Services Task Force, the government's major medical advisory panel, announced that they could no longer support routine mammographies for women under the age of 50 who were not in a high risk group for breast cancer.
They said that the number of cancer cases detected from such screening was too low, and that too many biopsies and further tests were being done in women who had hard-to-interpret test results but who turned out not to have the disease.
This new recommendation unleashed a tsunami of criticism from many breast cancer doctors, patient advocacy groups and women. In an msnbc.com poll, more than 80 percent of women said they were going to ignore the advice.
Emotional, snide -- and even paranoid -- accusations plagued the recommendation to end routine mammograms for women under 50. Some wondered why there were no true breast cancer experts on the panel. Still others suggested that the whole report was written with an eye toward the billions of dollars being spent on screening every year. And a few even wondered that if this was about men's health, rather than women's, would these scientists have been so quick to yank the plug on a screening test?
Critics of health reform sneered that this is what Obama has in mind for all of us if the government gets its cheap hands on health care -- cutbacks in crucial medical benefits now enjoyed by those with private insurance.
By Wednesday, Sebelius cried uncle, bulldozed over the task force and told women under 50 to forget the new advice, keep doing what they had been doing and talk with their doctors about screening.
So how did the poor scientists of the U.S. Preventive Services Task Force go from being the "gold standard" for deciding what works in medical screening (this is according to the Web site of Sebelius' own agency!) on Monday, to a bunch of irrelevant nerds by Wednesday?
That's because data and evidence have not, do not and never will be the sole determinants of health coverage.
Data-driven health care
The mission of this task force is is to evaluate the benefits of preventive services based only on data in the peer-reviewed literature and input from experts at other federal agencies like the Centers for Disease Control and Prevention, the National Institutes of Health, Veterans Affairs and other professional medical groups.
They are instructed to make their recommendations about the value of screening tests, such as mammograms, with little attention to the economic cost to society.
The critics were right about one thing: It is true that the committee recommendations are the sort of thing the Obama administration has in mind as part of health reform. But not as a way to ration care for the insured. The administration has been talking endlessly about using better data to figure out what works and what to pay for.
In this case, the task force found that screening all women in their 40s led to too many false positives and too much unnecessary follow-up testing for the number of lives it saved. They did not say that no lives were being saved. They said not as many as everyone thought. And not enough to justify asking every woman under 50 to get a mammogram every year.
Well, women fear breast cancer. So do their husbands, brothers, sons and fathers. There is no way testing for an especially dread disease that is at least somewhat effective is going to be cut back without screaming protests.
What's accurate vs. what's right
The data does not tell us what to do in setting a standard for testing or paying for it -- ever. We have to base these kinds of decisions on both data and values. How much do we fear getting a disease? How much are women willing to go through to avoid getting it? How much do we value saving younger lives and those of mothers of young children? These are as much ethics and policy question as they are issues of the facts.
Equally important, once a practice is firmly in place, such as screening for breast cancer, it is very hard to change beliefs and deeply held convictions overnight. If you tell women to get tested early and often for the better part of two decades, if you tout early detection as one of the triumphs of the "war on cancer" and if you stick breast self-examination cards into every shower stall in America then one day say, er, nevermind, forget it -- don't expect that to go down very well.
Screening is what responsible and health-conscious women do to take control of their bodies and prevent disease. Those are commendable and powerful virtues, and -- it seems --more compelling than a pile of bland data.
Doing the right thing and taking the time to protect yourself against breast cancer has moral weight that policy makers, as Secretary Sebelius found out, ignore at their peril.
There is no reason to doubt the accuracy of the scientists' finding that evidence does not support routine mammography for most women under 50. But there is every reason to doubt that the numbers they compiled will be sufficient to overturn a medical practice that carries so much ethical weight for women.
contribute a comment
Your contributions to the conversation are very much appreciated. We do have a few simple guidelines, though. Be civil. Stay on topic. We reserve the right to remove comments that violate the aforementioned guidelines. One more thing: comments are moderated, so it may take a little while for your comment to be posted. Thanks.











comments
Dr. Caplan is correct that policy is made with many inputs, not just data and scientific evidence. What is often forgotten is that the USPSTF's first and enduring recommendation from 1986 to 2002 was the same recommendation basically as they have reverted to now - screening beginning at age 50. The 2002 change in recommendation (to age 40) was never based on evidence, but more on significant political pressure.
We need a body (the USPSTF) which objectively and unbiasedly evaluates data and science and makes recommendations based on that. Then decision-making bodies such as medical coverage advisory committees for insurance companies or Medicare and corporate benefits managers will decide what is actually covered. We also have to recognize that voluntary health organizations and specialty medical societies have vested biases in how they evaluate data and scientific evidence, often giving recommendations that are more expansive than warranted by the available evidence.
Instead of complaining about the high cost of care in the US and then saying that for any individual patient (and in this case for the population) cost should not be a consideration, cost considerations should be a component of what is covered, given our limited resources. Population medicine practiced by the USPSTF is an important input, but once again brings up the Rose paradox - what benefits a large population does not always benefit individuals. And moving the median is often more beneficial to populations, while attending to the extremes benefits individuals but doesn't necessarily move the median.
- by Halley Faust,MD, MPH on Nov 27, 2009 at 1:19 PM | link
Reading Dr. Caplan's commentary alone, one might come away with the impression the US Preventive Services Task Force merely provided a nerdy review of "bland data", without expressly acknowledging how values help steer individuals to decisions that are "right" for them. The content of the report is available for anyone who wishes to see it, and it belies such an impression.
http://www.ahrq.gov/clinic/uspstf09/breastcancer/brcanrs.htm
What the Task Force states is that the evidence is not so strong as to support a "routine" screening practice for all women in the age range of 40 to 49. The report offers ample detail regarding both the narrow but actual potential benefits and significant risk of harm from "routine" mammography in this age group.
The second sentence of the report, however, should be hard to miss. It offers a strong articulation of how individual patients and their physicians need to make "right" decisions in light of their values and their personal estimation of risks and benefits. It says,
"The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms."
I can't think of a more direct and appropriate description of how to make an important, but difficult, clinical decision, where benefits and harms stack both ways. To me at least, this statement eloquently acknowledges the necessity of individual judgment toward that which is "right", and not merely "accurate". It is unfortunate that this element of the Task Force's report was overshadowed.
Stefan G. Kertesz, MD, MSc
- by Stefan Kertesz MD on Dec 7, 2009 at 10:50 PM | link